



Fermenta Biotech Limited

CIN: L99999MH1951PLC008485

Regd. Office: A - 1501, Thane One, DIL Complex, Ghodbunder Road,
Majiwade, Thane (W) - 400 610, Maharashtra, India.

Tel. : +91-22-6798 0888 Email : info@fermentabiotech.com,

Website : www.fermentabiotech.com



August 11, 2026

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001
Scrip Code: **506414**

National Stock Exchange of India Limited

Exchange Plaza, Plot No. C/1,
G Block, Bandra - Kurla Complex,
Bandra (East), Mumbai 400 051
Trading Symbol: **FERMENTA**

Dear Sir,

Sub: Outcome of Board Meeting and Unaudited Financial Results – pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').

We write to inform you that the Board of Directors of the Company, at its meeting held on August 11, 2026, has, *inter alia*, approved the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026.

We are also enclosing herewith the Limited Review Reports on the aforesaid results (Standalone and Consolidated) issued by M/s. SRBC & Co. LLP, Chartered Accountants, Statutory Auditors of the Company with an unmodified opinion on the above-mentioned financial results dated August 11, 2026.

Kindly take the above on record.

The Board meeting commenced at 11:00 a.m. (IST) and concluded at 01:10 p.m. (IST).

Thanking you,

Yours faithfully,

For **Fermenta Biotech Limited**

Varadvinayak Khambete

Company Secretary & Head - Legal

Membership No. A33861

Encl: As above

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**Review Report to
The Board of Directors
Fermenta Biotech Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Fermenta Biotech Limited (the "Company") for the quarter ended June 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S R B C & CO LLP

Chartered Accountants

ICAI Firm registration number: 324982E/E300003

**per Poonam Todarwal**

Partner

Membership No.: 136454

UDIN: 26136454PYHKWL4314

Mumbai

August 11, 2026





Fermenta Biotech Limited

CIN:L99999MH1951PLC008485

Regd. Office: A-1501, Thane One, DIL Complex, Ghodbunder Road, Majiwada, Thane (West) 400 610, Maharashtra, India.

Tel: +91-22-67980888, Fax: +91-22-67980999, Email: info@fermentabiotech.com, Website: www.fermentabiotech.com


STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026					₹ in Lakhs
Sr. No.	Particulars	Standalone			
		Quarter Ended		Year Ended	
		Unaudited	Audited	Unaudited	Audited
		June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026
			(Note 9)		
1	Income				
	a) Revenue from operations (refer note 4)	11,183.93	10,987.63	11,901.87	45,025.27
	b) Other income	489.66	609.88	884.08	2,389.89
2	Total Income (a+b)	11,673.59	11,597.51	12,785.95	47,415.16
3	Expenses				
	a) Cost of materials consumed (refer note 6)	4,485.76	3,641.51	3,179.01	16,656.99
	b) Purchases of stock-in-trade	130.19	231.73	536.38	1,150.05
	c) Change in inventories of finished goods, stock-in-trade and work-in-progress	(1,062.56)	(384.66)	908.90	(2,470.98)
	d) Employee benefits expense (refer note 10)	2,005.15	1,832.04	1,897.28	7,413.83
	e) Finance costs	253.91	276.59	310.50	1,148.44
	f) Depreciation and amortisation expense	518.61	508.19	554.73	2,093.63
	g) Other expenses	3,327.95	3,483.27	3,127.23	13,195.70
	Total expenses (a to g)	9,659.01	9,588.67	10,514.03	39,187.66
4	Profit before tax (2-3)	2,014.58	2,008.84	2,271.92	8,227.50
5	Exceptional items income / (expenses) (refer note 7 & 8)	-	907.14	-	696.62
6	Profit after Exceptional Items and before tax (4-5)	2,014.58	2,915.98	2,271.92	8,924.12
7	Tax expense				
	a) Current tax	436.09	377.45	400.38	1,460.72
	b) Deferred tax charge	79.91	381.25	248.16	1,035.04
	Total tax expense (a+b)	516.00	758.70	648.54	2,495.76
8	Profit for the period/year after tax (6-7)	1,498.58	2,157.28	1,623.38	6,428.36
9	Other Comprehensive Income				
(A)	i) Items that will not be reclassified to Profit or Loss	-	32.68	-	32.68
	ii) Income tax thereon	-	(8.23)	-	(8.23)
(B)	Items that will be reclassified to Profit or Loss				
	(i) Net fair value change in investment in equity instruments through other	(0.68)	(4.37)	6.82	(6.68)
	ii) Income tax thereon.	0.17	1.68	-	1.68
	Total other comprehensive Income/(Loss)	(0.51)	21.76	6.82	19.45
10	Total Comprehensive Income for the period/year (8+9)	1,498.07	2,179.04	1,630.20	6,447.81
11	Paid-up equity share capital (Face value ₹ 5/- per share)	1,434.03	1,433.53	1,458.45	1,433.53
12	Other equity (excluding revaluation reserve)				40,848.04
13	Earnings per equity share of ₹ 5 each (not annualised)				
	Earnings per equity share of ₹ 5 each before exceptional items				
	a) ₹ Basic	5.23	5.26	5.57	20.43
	b) ₹ Diluted	5.13	5.21	5.56	20.27
	Earnings per equity share of ₹ 5 each after exceptional items				
	a) ₹ Basic	5.23	7.49	5.57	22.13
	b) ₹ Diluted	5.13	7.43	5.56	21.96
	See accompanying notes to the Standalone financial results				



NOTES:

1. Segment Information					₹ in Lakhs
Particulars	Standalone				
	Quarter Ended			Year Ended	
	Unaudited	Audited	Unaudited	Audited	
	June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026	
		(Note 9)			
Segment revenue					
- Bulk drugs/chemicals	11,341.96	11,270.04	11,672.43	44,372.65	
- Property (Refer Note 4)	199.36	188.43	355.22	951.27	
- Unallocated (Refer Note 5)	132.27	139.04	758.30	2,091.24	
Total Income	11,673.59	11,597.51	12,785.95	47,415.16	
Segment results					
- Bulk drugs/chemicals (refer note 6)	2,129.38	2,124.17	2,215.45	8,260.73	
- Property	6.84	22.22	156.95	210.98	
- Unallocated (Net) (Refer Note 5)	132.27	139.04	210.02	904.23	
Total Profit before tax and finance cost	2,268.49	2,285.43	2,582.42	9,375.94	
- Finance costs	(253.91)	(276.59)	(310.50)	(1,148.44)	
Total Profit before Exceptional item and tax	2,014.58	2,008.84	2,271.92	8,227.50	
- Exceptional item (refer note 7 & 8)	-	907.14	-	696.62	
Total Profit before tax	2,014.58	2,915.98	2,271.92	8,924.12	
Segment Assets					
- Bulk drugs/chemicals	54,075.00	52,996.08	48,884.19	52,996.08	
- Property	862.58	856.88	1,791.39	856.88	
- Unallocated*	12,709.51	11,382.64	12,288.72	11,382.64	
Total Segment Assets	67,647.09	65,235.60	62,964.30	65,235.60	
Segment Liabilities					
- Bulk drugs/chemicals	9,451.18	8,971.77	8,024.86	8,971.77	
- Property	3,894.07	2,907.36	4,193.29	2,907.36	
- Unallocated*	10,409.27	11,074.90	11,052.53	11,074.90	
Total Segment Liabilities	23,754.52	22,954.03	23,270.68	22,954.03	


(*Refer note 5 for transfer of assets and liabilities pertaining to the Environment Division).




- 2 The above unaudited standalone financial results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 11th August, 2026. The results of the Company are available for investors at www.fermentabiotech.com, www.bseindia.com and www.nseindia.com in accordance with the provision of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015
- 3 These unaudited financial results have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules 2015 (as amended) ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 4 During the previous year, the company sold a portion of its investment property comprising freehold land situated at Village Takawe. The gain arising from such sale amounted to ₹162.89 lakhs for the quarter ended June 30, 2025 and the year ended March 31, 2026 (quarter ended June 30, 2026: ₹Nil; quarter ended March 31, 2026: ₹Nil). The said income has been recognized under 'Revenue from Operations' pertaining to the Property Segment.
- 5 During the previous year, the company transferred its Environment Division to its wholly owned subsidiary, Fermenta Environment Solutions Private Limited, as a going concern on a slump sale basis with effect from October 01, 2025, for a consideration of ₹ 1,900 lakhs.
- 6 During the current period, the company has consumed semi-finished inventory provided for in the earlier year towards the production of animal feed and accordingly such provision has been reversed for the quarter ended June 30, 2026 is ₹ 205.00 lakhs, (for the quarter ended March 31, 2026 is ₹ 316.78 lakhs, for the quarter ended June 30, 2025 is ₹ Nil lakhs and the year ended March 31, 2026 is ₹ 1,023.73 lakhs).
- 7 In the earlier years, the company had recognised provision against certain receivables and trade receivables. The company recovered part amount of ₹ 907.14 lakhs against these provided balances and accordingly such provision was reversed and recorded as an exceptional items in the year and quarter ended March 31, 2026.
- 8 During the previous year, the company assessed the potential impact of increased employee benefit obligations arising from the implementation of the Labour Codes, based on its best estimate and in consultation with external experts. Accordingly, the Company recognised a provision of ₹210.52 lakhs for the year ended March 31, 2026 in accordance with Ind AS 19, Employee Benefits, which was disclosed as exceptional item.
- 9 The figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2026 and the unaudited published year to date figures upto the nine months ended December 31, 2025 which were subjected to a limited review by the statutory auditors.
- 10 During the quarter, the Company has granted 3,95,400 employee stock options to the eligible employees of the company at an exercise price of ₹ 83.67 per option exercisable into equivalent equity share of ₹ 5 each subject to the fulfilment of vesting conditions, under "The Fermenta Biotech Limited - Employee Stock Option Scheme 2025", as approved by the shareholders of the Company on 12th August 2025.
- 11 Figures of the previous periods have been regrouped/ reclassified wherever necessary to conform to the current period classification.

Place: Thane

Date : 11th August, 2026




Prashant Nagre
Managing Director
DIN-09165447

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**Review Report to
The Board of Directors
Fermenta Biotech Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Fermenta Biotech Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), its associate for the quarter ended June 30, 2026 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

Sr. No.	Name of the Entity	Relationship
1	Fermenta Biotech Limited	Parent
2	Fermenta Biotech (UK) Limited	Subsidiary
3	Fermenta Biotech GmbH	Subsidiary
4	Fermenta Biotech USA LLC	Subsidiary
5	Fermenta USA LLC	Subsidiary
6	Fermenta Environment Solutions Private Limited	Subsidiary
7	Health and Wellness India Private Limited	Associate

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information



SRBC & COLLP

Chartered Accountants

required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The accompanying Statement includes the unaudited interim financial results and other financial information, in respect of:
- 3 subsidiaries, whose unaudited interim financial results include total revenues of Rs. 1,648.16 lakhs, total net (loss) after tax of Rs. (398.17) lakhs, total comprehensive (loss) of Rs. (398.17) lakhs, for the quarter ended June 30, 2026, as considered in the Statement which have been reviewed by their respective independent auditors.

The independent auditor's reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries, joint operations, joint ventures and associates is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

7. The accompanying Statement includes unaudited interim financial results and other unaudited financial information in respect of:
- 1 subsidiary, whose interim financial results and other financial information reflect total revenues of Rs. Nil, total net (loss) after tax of Rs. (0.08) lakhs, total comprehensive loss of Rs. (0.08) lakhs, for the quarter ended June 30, 2026.
 - 1 associate, whose interim financial results includes the Group's share of net profit of Rs. Nil and Group's share of total comprehensive income of Rs. Nil for the quarter ended June 30, 2026.

The unaudited interim financial results and other unaudited financial information of these subsidiaries and associate have not been reviewed by their auditors and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of these subsidiaries and associate, is based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Our conclusion on the Statement in respect of matters stated in para 6 and 7 above is not modified with respect to our reliance on the work done and the reports of the other auditors and the financial results certified by the Management.

For SRBC & CO LLP

Chartered Accountants

ICAI Firm registration number: 324982E/E300003

Poonam Todarwal

per Poonam Todarwal

Partner

Membership No.: 136454



UDIN: 26136454E91PNQ3426

Mumbai

August 11, 2026



Fermenta Biotech Limited
CIN:L99999MH1951PLC008485
Regd. Office: A-1501, Thane One, DIL Complex, Ghodbunder Road, Majiwada, Thane (West) 400 610, Maharashtra, India.
Tel: +91-22-67980888, Fax: +91-22-67980999, Email: info@fermentabiotech.com, Website: www.fermentabiotech.com

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026					₹ in Lakhs
Sr. No.	Particulars	Consolidated			
		Quarter Ended		Year Ended	
		Unaudited	Audited	Unaudited	Audited
		June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026
		Note 8			
1	Income				
	a) Revenue from operations (refer note 4)	12,182.12	12,158.34	13,626.27	52,542.94
	b) Other income	437.38	506.39	877.13	2,238.52
2	Total Income (a+b)	12,619.50	12,664.73	14,503.40	54,781.46
3	Expenses				
	a) Cost of materials consumed (refer note 5)	3,875.32	3,713.66	2,751.83	14,875.93
	b) Purchases of stock-in-trade	978.04	147.65	1,562.21	4,364.20
	c) Change in inventories of finished goods, stock-in-trade and work-in-progress	(647.34)	311.24	884.88	(47.02)
	d) Employee benefits expense (refer note 9)	2,300.62	2,132.77	2,035.00	8,259.43
	e) Finance costs	253.91	281.86	310.50	1,153.76
	f) Depreciation and amortisation expense	519.56	510.89	581.23	2,169.68
	g) Other expenses	3,870.24	3,852.81	3,569.04	15,107.01
	Total expenses (a to g)	11,150.35	10,950.88	11,694.69	45,882.99
4	Profit before tax (2-3)	1,469.15	1,713.85	2,808.71	8,898.47
5	Exceptional Items income / (expenses) (refer note 6 & 7)	-	907.14	-	687.58
6	Profit after Exceptional Items and before tax (4-5)	1,469.15	2,620.99	2,808.71	9,586.05
7	Tax expense				
	a) Current tax	436.09	379.71	400.38	1,525.58
	b) Deferred tax charge	79.91	381.25	248.16	1,035.04
	Total tax expense (a+b)	516.00	760.96	648.54	2,560.62
8	Profit for the period /year after tax but before share of profit of an associate (6-7)	953.15	1,860.03	2,160.17	7,025.43
9	Share of profit of an associate	-	-	-	-
10	Net Profit after tax (8-9)	953.15	1,860.03	2,160.17	7,025.43
11	Attributable to:				
	- Owners of the parent	973.81	1,918.99	2,183.49	7,176.53
	- Non-controlling interests	(20.66)	(58.96)	(23.32)	(151.10)
12	Other Comprehensive Income				
	Items that will not be reclassified to Profit or Loss				
	i) Remeasurements of defined benefit plan	-	36.63	-	36.63
	ii) Income tax thereon	-	(8.23)	-	(8.23)
	Items that will be reclassified to Profit or Loss				
	i) Exchange differences in translating the financials statements in foreign currency	30.20	(179.69)	(273.11)	(684.31)
	ii) Net fair value change in investment in equity instruments through other comprehensive income (net)	(0.68)	(4.37)	6.82	(6.68)
	iii) Income tax thereon.	0.17	1.68	-	1.68
	Total other comprehensive Income	29.69	(153.98)	(266.29)	(660.91)
13	Total Comprehensive Income for the period/year (10+12)	982.84	1,706.05	1,893.88	6,364.52
	Attributable to:				
	- Owners of the parent	1,003.50	1,765.01	1,917.20	6,515.62
	- Non-controlling interests	(20.66)	(58.96)	(23.32)	(151.10)
14	Paid-up equity share capital (Face value ₹ 5/- per share)	1,434.03	1,433.53	1,458.45	1,433.53
15	Other equity (excluding revaluation reserve)				39,187.85
16	Earnings per equity share of ₹ 5 each (not annualised)				
	Earnings per equity share of ₹ 5 each before exceptional items				
	a) ₹ Basic	3.40	3.51	7.49	23.02
	b) ₹ Diluted	3.34	3.48	7.47	22.16
	Earnings per equity share of ₹ 5 each after exceptional items				
	a) ₹ Basic	3.40	6.66	7.49	24.70
	b) ₹ Diluted	3.34	6.61	7.47	24.51
	See accompanying notes to the Consolidated financial results				



NOTES:

1. Segment Information

₹ in Lakhs

Particulars	Consolidated			
	Quarter Ended			Year Ended
	Unaudited	Audited	Unaudited	Audited
	June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026
		Note 8		
Segment revenue				
- Bulk drugs/chemicals	11,739.16	12,399.63	13,389.89	51,472.17
- Property (Refer Note 4)	199.36	188.43	355.22	951.27
- Unallocated	680.98	76.67	758.29	2,358.02
Total Income	12,619.50	12,664.73	14,503.40	54,781.46
Segment results				
- Bulk drugs/chemicals (refer note 5)	1,905.05	2,053.73	2,752.23	9,331.20
- Property	6.84	22.22	156.95	210.98
- Unallocated (Net)	(188.83)	(80.24)	210.03	510.05
Total Profit before tax and finance cost	1,723.06	1,995.71	3,119.21	10,052.23
- Finance costs	(253.91)	(281.86)	(310.50)	(1,153.76)
Total Profit before Exceptional item and tax	1,469.15	1,713.85	2,808.71	8,898.47
- Exceptional item (refer note 6 & 7)	-	907.14	-	687.58
Total Profit before tax	1,469.15	2,620.99	2,808.71	9,586.05
Segment Assets				
- Bulk drugs/chemicals	52,962.55	52,329.04	48,694.99	52,329.04
- Property	862.58	856.88	1,791.39	856.88
- Unallocated	12,769.09	11,607.98	12,288.72	11,607.98
Total Segment Assets	66,594.22	64,793.90	62,775.10	64,793.90
Segment Liabilities				
- Bulk drugs/chemicals	10,300.10	9,903.30	9,715.69	9,903.30
- Property	3,894.07	2,907.36	4,193.29	2,907.36
- Unallocated	11,249.72	11,928.65	11,049.24	11,928.65
Total Segment Liabilities	25,443.89	24,739.31	24,958.22	24,739.31

SIGNED FOR IDENTIFICATION
BY *fl*
S R B C & CO LLP
MUMBAI



R

- 2 The above unaudited consolidated financial results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 11th August, 2026. The results of the Company are available for investors at www.fermentabiotech.com, www.bseindia.com and www.nseindia.com in accordance with the provision of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015
- 3 These unaudited consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules 2015 (as amended) ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 4 During the previous year, the Parent Company sold a portion of its investment property comprising freehold land situated at Village Takawe. The gain arising from such sale amounted to ₹162.89 lakhs for the quarter ended June 30, 2025 and the year ended March 31, 2026 (quarter ended June 30, 2026: ₹Nil; quarter ended March 31, 2026: ₹Nil). The said income has been recognized under 'Revenue from Operations' pertaining to the Property Segment.
- 5 During the current period, the Parent company has consumed semi-finished inventory provided for in the earlier year towards the production of animal feed and accordingly such provision has been reversed for the quarter ended June 30, 2026 is ₹ 205.00 lakhs, (for the quarter ended March 31, 2026 is ₹ 316.78 lakhs, for the quarter ended June 30, 2025 is ₹ Nil lakhs and the year ended March 31, 2026 is ₹ 1,023.73 lakhs).
- 6 In the earlier years, the Parent company had recognised provision against certain receivables and trade receivables. The Parent company recovered part amount of ₹ 907.14 lakhs against these provided balances and accordingly such provision was reversed and recorded as an exceptional items in the year and quarter ended March 31, 2026.
- 7 During the previous year, the Group assessed the potential impact of increased employee benefit obligations arising from the implementation of the Labour Codes, based on its best estimate and in consultation with external experts. Accordingly, the Group recognised a provision of ₹219.56 lakhs for the year ended March 31, 2026 in accordance with Ind AS 19, Employee Benefits, which was disclosed as exceptional item.
- 8 The figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2026 and the unaudited published year to date figures upto the nine months ended December 31, 2025 which were subjected to a limited review by the statutory auditors.
- 9 During the quarter, the Parent company has granted 3,95,400 employee stock options to the eligible employees of the company at an exercise price of ₹ 83.67 per option exercisable into equivalent equity share of ₹ 5 each subject to the fulfilment of vesting conditions, under "The Fermenta Biotech Limited - Employee Stock Option Scheme 2025", as approved by the shareholders of the Company on 12th August 2025.
- 10 Figures of the previous periods have been regrouped/ reclassified wherever necessary to conform to the current period classification.

Place: Thane

Date : 11th August, 2026



Prashant Nagre
Managing Director
DIN-09165447